What does this video actually claim?
@laurenpodcasts documents her first two days starting Wegovy, focusing on changes in appetite and "food noise." She reports feeling less hungry and experiencing reduced thoughts about food within 48 hours of her first injection.
The creator mentions starting at what appears to be the standard 0.25mg dose and describes immediate effects on her eating patterns. She uses terms like "food noise" and "binge" in her hashtags, suggesting she's using Wegovy to address compulsive eating behaviors.
Can semaglutide work this quickly?
Yes, some people do notice appetite changes within days of starting semaglutide. The drug reaches steady-state levels in 4-5 weeks, but initial effects can appear much sooner.
The STEP 1 trial (Wilding et al., NEJM, 2021) tracked weekly changes and found appetite suppression often began in the first week. Semaglutide slows gastric emptying and acts on brain appetite centers, so feeling less hungry on day 2 isn't unusual.
However, the 0.25mg starting dose is primarily for tolerance building. Most significant weight loss happens at the 2.4mg maintenance dose, which patients don't reach until week 16 of the standard titration schedule.
What about "food noise" claims?
The creator's description of reduced "food noise" matches documented effects of GLP-1 receptor agonists on food preoccupation. This isn't just marketing speak.
A study by Holst & Madsbad (Diabetes Care, 2022) found semaglutide reduces neural responses to food cues in brain imaging studies. Patients report fewer intrusive thoughts about food and less mental energy spent planning meals.
The STEP 6 trial specifically looked at binge eating episodes in people with obesity. Participants on 2.4mg semaglutide had 68% fewer binge episodes compared to 28% on placebo after 68 weeks. So her hashtag choice reflects a real clinical application.
What's missing from this early report?
Two days is far too early to draw meaningful conclusions about Wegovy's effectiveness. The creator doesn't mention common side effects that often appear in the first week.
Nausea affects 44% of people starting semaglutide, according to STEP trial data. Vomiting, diarrhea, and constipation are also common early side effects. The absence of side effect discussion gives an incomplete picture.
She also doesn't address the 16-week titration process required to reach therapeutic doses. Many people who feel great at 0.25mg struggle with higher doses where the real weight loss occurs.
What should you actually know?
Early appetite changes on Wegovy are normal and encouraging, but they don't predict long-term success. Real outcomes depend on reaching and tolerating higher doses over months.
The STEP trials showed average weight loss of 14.9% at 68 weeks, but 32% of participants didn't complete the studies. Dropout rates were highest during dose escalation phases due to gastrointestinal side effects.
If you're considering Wegovy, focus on the full treatment timeline rather than day-by-day changes. Most people need several months at maintenance doses to see the dramatic results shown in clinical trials.